Cystatin C and Albuminuria as Risk Factors for Development of CKD Stage 3: The Multi- Ethnic Study of Atherosclerosis (MESA) Shani Shastri, MD, MS, Ronit.

Slides:

Advertisements

Similar presentations

The Rise of Renal Pathology in Nephrology: Structure Illuminates Function Vivette D. D'Agati, MD, Michael Mengel, MD American Journal of Kidney Diseases.

Advertisements

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

Andrew Moran, MD, MPH, Ronit Katz, PhD, Nicolas L. Smith, PhD, Linda F

Differential Estimation of CKD Using Creatinine- Versus Cystatin C–Based Estimating Equations by Category of Body Mass Index Suma Vupputuri, PhD, Caroline.

Uric Acid and Long-term Outcomes in CKD

KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD Mark J. Sarnak, MD, MS, Roy Bloom, MD, Paul Muntner, PhD,

Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and.

Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis

Francesca Mallamaci, MD, Giovanni Tripepi, PhD

Association of Physical Activity and Renal Function in Subjects With and Without Metabolic Syndrome: A Review of the Third National Health and Nutrition.

Edmund J. Bini, MD, MPH, Aditi Kinkhabwala, MD, David S. Goldfarb, MD

A Decade After the KDOQI CKD Guidelines

Joseph A. Vassalotti, MD, Beth Piraino, MD, Lynda A. Szczech, MD

Cardiovascular Disease and CKD: Core Curriculum 2010

Impact of Comorbidities on Mortality in Managed Care Patients With CKD

Risk Factors for ESRD in Individuals With Preserved Estimated GFR With and Without Albuminuria: Results From the Kidney Early Evaluation Program (KEEP)

Recognition for Conservative Care in Kidney Failure

Anne M. Butler, PhD, Andrew F. Olshan, PhD, Abhijit V

Andrew Narva American Journal of Kidney Diseases

Cystatin-C and inflammatory markers in the ambulatory elderly

Evaluation of the Potential Living Kidney Donor

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the.

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Lifetime Incidence of CKD Stages 3-5 in the United States

Effect of Protein Restriction on Serum and Urine Phosphate in the Modification of Diet in Renal Disease (MDRD) Study Britt Newsome, MD, Joachim H. Ix,

The Kidney Early Evaluation Program (KEEP): Program Design and Demographic Characteristics of the Population Claudine T. Jurkovitz, MD, MPH, Yang Qiu,

Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Navdeep Tangri, MD, FRCPC, Daniel E. Weiner, MD, MS

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

Effect of Intensive Insulin Therapy and Pentastarch Resuscitation on Acute Kidney Injury in Severe Sepsis George Thomas, MD, MPH, Ethan M. Balk, MD,

David C. Mendelssohn, MD, FRCPC, Jay B. Wish, MD

CKD and Muscle Mitochondrial Energetics

Volume 88, Issue 5, Pages (November 2015)

Usability Testing and Acceptance of an Electronic Medication Inquiry System for CKD Patients Clarissa J. Diamantidis, MD, MHS, Marni Zuckerman, MA, Wanda.

Prediabetes as a Precursor to Diabetic Kidney Disease

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Michael F. Flessner, MD, PhD, Sharon B. Wyatt, PhD, Ermeg L

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Margaret T. Hicken, Ronit Katz, Deidra C. Crews, Holly J

A Timely Evaluation of the Psychometric Properties of the KDQOL-36

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Drug Dose Adjustments in Patients With Renal Impairment

Daniel T. Lackland, DrPH, David J.P. Barker, MD, PhD

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP)

Risk for Incident Renal Dialysis in a Managed Care Population

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD

Trial Quality in Nephrology: How Are We Measuring Up?

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2011: Executive Summary Adam T. Whaley-Connell, DO, MSPH, Joseph.

Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), Madhav V. Rao,

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

This Month in AJKD American Journal of Kidney Diseases

Dialysis Research and N-of-1 Trials: Made for Each Other?

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

Racial and Ethnic Differences in Albuminuria in Individuals With Estimated GFR Greater Than 60 mL/min/1.73 m2: Results From the Kidney Early Evaluation.

A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Adam Whaley-Connell, DO, MSPH

Daniel E. Weiner, MD, MS, Hocine Tighiouart, MS, John L

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

Update on Cystatin C: Incorporation Into Clinical Practice

Medication Adherence Behavior and Priorities Among Older Adults With CKD: A Semistructured Interview Study Dena E. Rifkin, MD, MS, M. Barton Laws, PhD,

Presentation transcript:

Cystatin C and Albuminuria as Risk Factors for Development of CKD Stage 3: The Multi- Ethnic Study of Atherosclerosis (MESA) Shani Shastri, MD, MS, Ronit Katz, DPhil, Michael G. Shlipak, MD, MPH, Bryan Kestenbaum, MD, MS, Carmen A. Peralta, MD, MAS, Holly Kramer, MD, David R. Jacobs, PhD, Ian H. de Boer, MD, MS, Mary Cushman, MD, David Siscovick, MD, MPH, Mark J. Sarnak, MD, MS American Journal of Kidney Diseases Volume 57, Issue 6, Pages 832-840 (June 2011) DOI: 10.1053/j.ajkd.2010.11.021 Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Cystatin C spline evaluates the shape of the relationship with incident rate ratios of chronic kidney disease stage 3 after adjusting for age, sex, and race and excluding the top and bottom 2.5%. Conversion factor for units: cystatin C in mg/L to nmol/L, ×74.9. American Journal of Kidney Diseases 2011 57, 832-840DOI: (10.1053/j.ajkd.2010.11.021) Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Annual unadjusted rate of incident chronic kidney disease stage 3 by quartiles of cystatin C and presence of microalbuminuria. Conversion factor for units: cystatin C in mg/L to nmol/L, ×74.9. Abbreviation: MA, microalbuminuria. American Journal of Kidney Diseases 2011 57, 832-840DOI: (10.1053/j.ajkd.2010.11.021) Copyright © 2011 National Kidney Foundation, Inc. Terms and Conditions